The rise of GLP-1 drugs like Ozempic and Wegovy is disrupting traditional patterns of the ‘munchies’, leading to potential interactions with cannabis edibles, changes in demand for product formulations, and new challenges for users and retailers.
Generations of cannabis users have treated the “munchies” as a predictable part of the high: THC kicks in, hunger follows and snacks become irresistible. That familiar pattern is now being complicated by GLP-1 medicines such as Ozempic, Wegovy, Mounjaro and Zepbound, which reduce appetite, help regulate blood sugar and slow gastric emptying, the process by which food leaves the stomach.
That slowing of digestion is central to the uncertainty. Cannabis edibles already have a delayed and uneven onset, with effects shaped by dose, metabolism, recent meals and product formulation. If a person taking a GLP-1 drug eats an edible, the THC may take longer to reach effect, increasing the risk that they take more before the first dose has fully kicked in.
There is still no solid clinical evidence showing exactly how GLP-1 medicines and THC interact, and researchers have not yet mapped the real-world consequences. Even so, the overlap between the two markets is growing, and some dispensaries are beginning to respond by steering customers towards lower-dose edibles, tinctures or inhaled products. Companies including Curio Wellness are also said to be working on clearer guidance at the point of sale.
The issue is not only about timing but also about appetite itself. THC stimulates cannabinoid receptors linked to hunger and reward, while GLP-1 drugs are designed to dampen cravings and support weight loss. That tension is already shaping demand for lower-dose products and formulations aimed at people who want fewer cravings and more predictable effects.
The topic may end up mattering beyond recreational use. The National Institute on Drug Abuse is funding a trial of tirzepatide, the active ingredient in Mounjaro and Zepbound, as a possible treatment for cannabis use disorder. Nora Volkow, the institute’s director, told Reuters that retrospective health-record studies had also suggested better cannabis-related outcomes among diabetes patients prescribed GLP-1 drugs than among those on other treatments.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
